|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 535 active entries
c -/ MEDBIOS
Toll free: +011-778-554-6691
Stock symbol: CDM
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Cardiomeds is a network concerned with developing new drug candidates for drug heart health through preventative therapy. They work through the central mechanism of chronic anti-inflammatory control and work at two different levels:
Our two class drug candidates are known as: 1) Cardiostatins which are VitD analogues working at the level of VDRs or calcium regulatory receptors while 2) epicardiostatins work as VitD agonists in the liver and kidneys where active forms of VitD are generated.
VitD is just beginning to be recognized and discovered for its potential effectiveness against chronic inflammatory-related diseases like diabetes T2, atherosclerosis and colon and, perhaps breast, cancers.
Cardio Health and Metabolic Perfluence:
Supporting stress-related conditions through heart health therapy is our goal. Does the use of nutritionals and their drugs (see: Cardiostatins and epicardiostatins, proposed above) that impact heart health correlate and could have a significant effect on the outcome of severity and save lives from conditioning cardiac strength or dysfunction.
At the molecular level, Ca2+ function, inflammation in the tissues and b.p. are all to be further investigated.
Cardio Health and Complex CHO (carbohydrates):
It is speculated at this time what the link is between supported heart health and and a regular intake of complex CHO in the diet. Noted, dietary fibre is associated with lower incidence and mortality from disease and (beta2->1)fructans, which have been found to have receptors in the lower gut may have far reaching effects past their receptors in the intestinal epithelial cells via cell signaling likened to VitD receptors (VDR) and Ca2+ receptors which are believed to be in 'parallel' in diseases like atheroslerosis, diabetesT2 and colon/breast cancers. Much more research will proceed in these areas in the coming years as to the receptor-cell signaling is concerned with dietary complex CHO intake and nutrition.
SKYENEWS: The ancilliary heart health drug to VitD also known to us as an epicardiostatin (also VitD receptor modulator, VDRM) is to be administered subcutaneously through the fatty tissues and released over a period of maintenance in body tissues proscribed by dosage as a % of b.wt. based on assessed VitD plasma levels. The epicardiostatin is believed to act on VitD receptors (VDRs) in various tissues throughout the body and is catabolized at a slower rate than VitD. Cancer prevention from this ancilliary drug would also be amenable from evidence over the correlation found between VitD's action and its incidence with sunlight irradiation (UV) underneath the skin. Dietary levels as already indicated would also limit VitD's action typically from plant and dairy sources. Manufacturing capacity and market for the drug would likely evolve from Scandinavia and Arabia for these reasons. Warning has been made for unlicensed and illicit drug trade amongst users in possible demarcated areas around the world. We propose a preventative health nutritional (PHN) plan to best administer drug-making and its use in specific countries that warrant its use.
A MEDBIOS CO.
Last update of this entry: April 13, 2016